[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100283732":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":20,"responsibleParty":37,"collaborators":39,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":7,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of Leicester","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Andrew Hall","Sleep Consultant","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Sahar Khodabakhsh, PhD","CONTACT","0116258","8070","sahar.khodabakhsh@uhl-tr.nhs.uk",[21],{"facility":22,"status":23,"city":24,"state":7,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Leicester Diabetes Centre, Leicester General Hospital","RECRUITING","Leicester","LE5 4PW","United Kingdom","UK",{"type":29,"coordinates":30},"Point",[31,32],-1.13169,52.6386,{"lat":32,"lon":31},[35],{"name":15,"role":16,"phone":36,"phoneExt":7,"email":19},"0116 258 8070",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[40],{"name":41,"class":6},"University Hospitals, Leicester","100283732","chronotype-of-patients-with-diabetes-and-effect-on-glycaemic-control-100283732",false,"NCT02973412","Chronotype of Patients With Diabetes and Effect on Glycaemic Control","Chronotype of Patients With Diabetes and Effect on Glycaemic Control: The CODEC Study","CODEC","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study\n2. T1DM or established T2DM (\\>6months since diagnosis)\n3. Male or Female\n4. Aged 18-75 years inclusive\n5. BMI less than or equal to 45kg\u002Fm² inclusive\n6. No known sleep disorders except Obstructive Sleep Apnoea (OSA)\n7. On any glucose-lowering therapy (T1DM or T2DM) or lifestyle modification for management of T2DM\n8. Good command of the English language\n\nExclusion Criteria:\n\n1. Participant is unwilling or unable to give informed consent\n2. Anyone without a good command of the English language\n3. Anyone \\\u003C18 years of age and \\>75 years of age\n4. BMI greater than 45 kg\u002Fm²\n5. A regular cannabis user i.e. weekly use\n6. Have a terminal illness\n7. A known sleep disorder that is not OSA\n8. Regular use of the following medicines i.e. Weekly use: (Wakefulness promoting agents Modafinil, Amphetamine derivatives, Methylphenidate; Sedatives including benzodiazepines, Z-drugs (zopiclone, zolpidem \\& zaleplon); Melatonin, including Circadin and melatonin analogues; Clonazepam and other drugs for nocturnal movement disorders).","ALL","18 Years","75 Years",{"count":54,"type":55},3447,"ESTIMATED","OBSERVATIONAL","The aim of this study is to explore the associations between chronotype and glycaemic control, cardiometabolic health and other lifestyle factors.",[59,60],"Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","2024-02-14",{"date":63,"type":64},"2024-02-15","ACTUAL",{"date":66,"type":64},"2016-12-07",{"date":68,"type":55},"2027-12-31",{"name":5,"class":6},1]